Joshua Phillips brings to BioTrove's Board considerable experience and multifaceted perspectives in building businesses. In addition to venture capital, Mr. Phillip's career has included strategy consulting, management, and engineering at Pratt and Whitney Aircraft, Russelectric, Inc., and the Lucas Group. Josh's investment interests at Catalyst span both the life sciences and technology markets, with particular interest in drug discovery tools and enterprise software. Mr. Phillip's previous investments at Catalyst include Novazyme Pharmaceuticals, Inc. and Castel, Inc. Mr. Phillips earned his BE in Electrical Engineering and Mathematics from Vanderbilt University and his MBA from Harvard Business School.
Dr. Enrico Petrillo is a General Partner of CB Health Ventures, LLC. Dr.
Petrillo joined CB Health Ventures after serving at Fletcher Spaght,
Inc. in the roles of Senior Consultant from 1984-1996 and as Partner and
Head of Healthcare Commercialization from 1991-1996. Fletcher Spaght is
an international strategic management consulting firm specializing in
research centers and emerging growth companies in the healthcare,
software, communications, and Internet industries.
Over the past ten years, Dr. Petrillo's advisory clients have included
numerous multi-national pharmaceutical, information technology, and
biotechnology firms, as well as medical services and device companies.
He has worked with numerous venture capital and private equity firms and
their investee companies and has been a key advisor for new ventures and
technology to major research centers such as Harvard Medical School,
Massachusetts Institute of Technology, Children's Hospital Medical
Center (Boston), Brigham and Women's Hospital, Beth Israel Deaconess
Medical Center, Massachusetts General and Dana Farber Cancer Institute.
Dr. Petrillo received his undergraduate degree from Tufts University
and medical degree from Tufts University School of Medicine. He
completed internship, residency, and fellowship training in General
Internal Medicine at Mt. Auburn Hospital (Harvard Medical School) and
presently serves as an Adjunct Assistant Professor of Medicine at Boston
University School of Medicine and Boston Medical Center.
Dr. Petrillo serves as a director of U.S. Genomics, Inc., Spherics,
Inc., BioTrove, Inc., and Morphotek, Inc., entities emanating from
technologies at MIT, Harvard, Brown, and Johns Hopkins Universities. In
addition, he was a venture investor in eBenX (NASDAQ: EBNX) as well as a
venture investor and board participant of Exact Sciences (NASDAQ: EXAS)
and XCare.net (NASDAQ: XCAR).
Mr. Erickson has served as president, CEO or a director for eight biomedical products companies, including Megabios Corporation, a gene therapy company (director, 1995-1998); DepoTech Corporation, a biopharmaceutical company in the drug delivery field (president and CEO, 1993-1998); Cholestech Corporation, a diagnostics company in point-of-care cholesterol testing and screening (president and CEO, 1991-1993); and most recently, Immunicon Corporation (NASDAQ-GM:IMMC), a company focused on cell- and molecular-based human diagnostic and life science research products and analytical services to pharmaceutical and biotechnology companies (CEO, 1999-2005), where he also served as chairman of the board since 1998. Earlier in his career he held senior management positions with Amersham International and Serono. Mr. Erickson earned BS and MS degrees from the Illinois Institute of Technology, and an MBA from the Harvard Business School. He did military service as an officer in the U.S. Navy, including duty aboard the U.S.S. Nautilus, the world's first nuclear submarine.
Dr. Critchfield has been President of Myriad Genetic Laboratories, Inc. since July 1998. Prior to Myriad, Dr. Critchfield was Senior Vice President, Chief Medical and Scientific Officer of Quest Diagnostics (formerly Corning Clinical Laboratories). He is a sought-after consultant, working with various national government, university, and healthcare organizations to improve disease testing for the public. Dr. Critchfield has served as a reviewer and study section chair for numerous SBIR, R01 and STTR grant applications in biomedical computing for the National Institutes of Health (NIH). He has also been a reviewer for the Clinical Chemistry journal. Dr. Critchfield received his M.D. from the University of Utah and his M.S. in Biophysical Sciences from the University of Minnesota. He is Board Certified in Clinical Pathology.
